Miri Schamroth Pravda

Background: Data regarding risk factors for superficial throm-bophlebitis (STP) cases presenting to a hospital is limited.Objectives: To investigate and stratify clinical and laboratory risk factors for STP.Methods: We conducted a retrospective case control study comparing patients presenting to the emergency department with STP and age-and gender-matched controls. We collected data on multiple risk factors and five blood indices.Results: The study comprised 151 patients and matched con-trols. Patients with STP were more likely to have varicose veins (43.7% vs. 5.3%, P < 0.001), recent immobilization (14.6% vs. 1.3%, P < 0.001), obesity (36.4% vs. 18.5%, P = 0.001), a history of venous thromboembolism (VTE) or STP (27.2% vs. 0.7%, P < 0.001), and inherited thrombophilia (9.3% vs. 1.3%, P = 0.002). Following multivariate analysis, all five risk fac-tors remained significant, with a history of VTE or STP asso-ciated with the largest risk (odds ratio [OR] 35.7), followed by immobilization (OR 22.3), varicose veins (OR 12.1), inher-ited thrombophilia (OR 6.1), and obesity (OR 2.7). Mean plate-let volume was higher (8.5 vs 7.9 fl, P= 0.003) in STP casesConclusions: A history of VTE or STP, immobilization, varicose veins, inherited thrombophilia, and obesity serve as indepen-dent clinical risk factors for STP presenting to hospital.

Coronary artery disease (CAD) is a significant cause of illness and death amongst women. The pathophysiology, manifestations, and outcomes of CVD and CAD differ between sexes. These sex differences remain under-recognized. The aim of this review is to highlight and raise awareness of the burden and unique aspects of CAD in women. It details the unique pathophysiology of CAD in women, cardiovascular risk factors in women (both traditional and sex-specific), the clinical presentation of CAD in women, and the range of disease in obstructive and non-obstructive CAD in women.

In this review, the authors re-examine the role of aspirin in the primary prevention of cardiovascular disease. They discuss the history of the use of aspirin in primary prevention, the current guidelines, and the recent evidence surrounding aspirin use as primary prevention in special populations such as those with moderate cardiovascular risk, diabetes mellitus, and the elderly.

A 37-year-old male was admitted with an atypical presentation of central nervous system (CNS) aspergillosis while on ibrutinib therapy for a CNS relapse of mantle cell lymphoma. This case highlights the importance of a high clinical suspicion of opportunistic infections in patients receiving small-molecule kinase inhibitors. This report includes a review of reported cases of Aspergillus infections in patients receiving ibrutinib and the shared features of these cases.